COO Stock Jumps As Earnings Beat Clears Recall Overhang

The Cooper Companies Inc. stocks have been trading up by 7.38 percent following upbeat sentiment around its latest earnings momentum.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading COO

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways Traders Need To Know

Record Q2 2026 revenue of $1.08B, up 8% year over year and ahead of the roughly $1.05B consensus, keeps COO’s multi-year growth trend intact.
Adjusted Q2 EPS climbed 26% to $1.21, topping the $1.10 estimate and marking COO’s tenth straight earnings beat, while GAAP EPS fell to -$0.40 on a $271.6M litigation charge.
Fiscal 2026 guidance calls for non-GAAP EPS of $4.58–$4.66 and revenue of $4.285–$4.321B, essentially matching Street expectations and backed by a >$2.2B free cash flow target for 2026–2028.
Agreements resolving most CooperSurgical fertility media recall claims remove a major headline risk as both main COO segments grew 8% with a 27% non-GAAP operating margin.
Street shops Piper Sandler, Mizuho, and BNP Paribas trimmed price targets but stayed Overweight/Outperform, with average targets in the high $80s–mid-$90s versus COO trading in the low $60s.

Live Update At 12:32:26 EDT: On Friday, June 05, 2026 The Cooper Companies Inc. stock [NASDAQ: COO] is trending up by 7.38%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

The Cooper Companies Inc. just gave traders a clean technical and fundamental catalyst combo. On 2026/06/05, COO gapped up from $65.24 and squeezed to $67.60 before settling near $66.60, extending a steady climb off the high-$50s seen in mid-May. That is a clear shift from grinding range to breakout behavior.

Under the hood, COO is not a story stock; it is a slow-and-steady compounder. Revenue over the last year sits around $4.09B with high 65.4% gross margins and healthy 27.2% EBITDA margins. Net margins near 9% are decent for a medical products name, and leverage looks controlled with total debt-to-equity of 0.3 and interest coverage at 11.7 times.

More Breaking News

For valuation, COO trades at roughly 3.8 times sales and about 39.7 times earnings, not cheap on headline P/E but more reasonable against its cash flow profile and history of premium multiples. Returns on equity in the mid-single digits leave room for improvement, but strong free cash flow per share and a solid balance sheet give COO firepower for buybacks and growth initiatives. For active traders, this backdrop supports the idea that pullbacks in COO may keep attracting dip-buyers as long as earnings momentum holds.

Why Traders Are Watching COO After This Earnings Beat

COO’s latest quarter is the kind of setup momentum traders look for: strong numbers, a cleaned-up story, and a stock that was beaten down ahead of the print. The company reported Q2 2026 revenue of $1.08B, up 8% year over year (5% organically), and non-GAAP EPS of $1.21, up 26%. Both beat consensus. This was COO’s tenth straight quarter of topping earnings expectations, which is not a fluke; it is a pattern of under-promising and over-delivering.

The twist is on the GAAP side. COO printed GAAP EPS of -$0.40 thanks to a $271.6M litigation charge tied to the 2023 CooperSurgical fertility media recall. For headline readers, a negative EPS print can look ugly. But the company also reached agreements to resolve most of those recall claims. For traders, that means a big overhang is finally fading just as the core business posts record revenue and a 27% non-GAAP operating margin.

Guidance from COO backs up the “steady grinder” narrative. Management now sees fiscal 2026 non-GAAP EPS at $4.58–$4.66 and revenue at $4.285–$4.321B, essentially right in line with the Street and even a touch above consensus EPS at the midpoint. On top of that, COO is targeting more than $2.2B in free cash flow across 2026–2028.

Analysts are cautious but constructive. Piper Sandler cut its COO price target to $86 from $94, and Mizuho trimmed to $85 from $100, yet both stayed Overweight/Outperform. BNP Paribas nudged its target to $95 from $96 and still calls COO Outperform. With the stock around the low $60s and the average target clustered in the high $80s to mid-$90s, the Street is signaling upside while demanding continued execution.

Conclusion

For active traders, COO is now a classic “show-me” earnings story with a chart finally waking up. The daily action around 2026/06/04–2026/06/05 shows strong buying after earnings, with COO ramping from about $61 to above $66 and holding gains intraday. Five-minute candles show tight consolidations and higher lows through midday, suggesting real demand rather than a one-and-done spike.

Fundamentally, COO’s two engines, CooperVision and CooperSurgical, both posted 8% revenue growth in Q2 with expanding non-GAAP margins. The company is also pushing harder into growth markets: CooperVision named Muru Annamalai President of Asia-Pacific, signaling that COO wants to lean into higher-growth regions for its contact lens business. Cash flow is backing those ambitions, with Q2 free cash flow strong and management targeting over $2.2B from 2026–2028.

At the same time, COO is not a risk-free swing. The recall saga still shows up in GAAP numbers, and guidance calls for mid-single-digit organic growth, not a hyper-growth runway. Traders need to respect key price levels, monitor how COO trades around earnings gaps, and stay nimble if the stock starts to fade back toward the low $60s. As Tim Bohen, lead trainer with StocksToTrade says, “Success in trading is more about cutting losses quickly than finding winners.”, so anyone trading COO needs to stay disciplined with risk management even when the chart looks strong.

As Tim Sykes likes to say, “Patterns repeat, but they don’t always complete.” With COO, the pattern is consistent earnings beats, heavy prior selling, and now a litigation overhang that is finally easing. The trade, as always, is to study the chart, know the catalyst, and be ready to cut losses fast if the thesis breaks. This analysis is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!